Market Place
Sourcing Support
Lupin receives FDA tentative approval for HIV treatment generic
07 Dec 2024 //
EXPRESSPHARMA
ViiV To Present Dovato Vs Biktarvy Trial Data At AIDS 2024
16 Jul 2024 //
INDIANPHARMAPOST
ViiV Healthcare To Present Dovato Vs Biktarvy Trial Data At AIDS 2024
15 Jul 2024 //
BUSINESSWIRE
ViiV Healthcare announces FDA Approval of Dovato for Adolescents Living with HIV
08 Apr 2024 //
BUSINESSWIRE
ViiV Health announces new packaging option now available in the U.S. for Dovato
05 Feb 2024 //
BUSINESSWIRE
Colombia to seek compulsory license on ViiV`s dolutegravir
05 Oct 2023 //
FIERCE PHARMA
GSK`s ViiV to lean on HIV portfolio ahead of dolutegravir patent expiration
28 Sep 2023 //
ENDPTS
Viatris Announces U.S. FDA Approval of a Paediatric Formulation of Abacavir
05 Sep 2023 //
PR NEWSWIRE
Lupin gets FDA tentative approval for dolutegravir tablets for oral suspension
04 Jul 2023 //
PHARMABIZ
Lupin`s Generic Dolutegravir Sodium Receives Approval in the U.S.
03 Jul 2023 //
FDA
Lupin gets USFDA nod for Dolutegravir, Emtricitabine and Tenofovir tablets
31 Jan 2023 //
ECONOMIC TIMES
Diabetes, patented TB, HIV drugs enter essential list
13 Sep 2022 //
ECONOMICTIMES
Exavir to publish PC data for ultra-long-acting dolutegravir prodrug XVIR-120
09 Jun 2022 //
GLOBENEWSWIRE
FDA Approves ViiV’s Triumeq PD for Children With HIV
01 Apr 2022 //
BLOOMBERG LAW
GSK announces $1.25 bln settlement between ViiV Healthcare, Gilead
02 Feb 2022 //
REUTERS
ViiV seeks FDA approval for dispersible single tablet regimen with dolutegravir
05 Oct 2021 //
PHARMABIZ
ViiV seeks FDA approval for dispersible single tablet regimen with dolutegravir
05 Oct 2021 //
PHARMABIZ
ViiV submits FDA application for dispersible single tablet regimen dolutegravir
04 Oct 2021 //
PRESS RELEASE
ViiV Healthcare presents three-year switch data for Dovato
29 Sep 2021 //
BUSINESSWIRE
Shionogi licenses out 3rd-gen HIV asset to ViiV
29 Sep 2021 //
FIERCEBIOTECH
PrEP updates and new products at IAS 2021
08 Sep 2021 //
WHO
Virologic, Clinical Failure Rates Low With Dolutegravir: Presented at IAS
20 Jul 2021 //
FIRSTWORDPHARMA
HIV generic drug for babies distributed in Africa, says UNITAID
06 Jul 2021 //
REUTERS
Takeda launches rare disease diagnosis programme for patients
30 Jun 2021 //
PHARMABIZ
The Food and Drug Administration approved revisions to the TRIUMEQ
12 Mar 2021 //
FDA
Pfizer COVID-19 vaccine set to generate sales of $30 billion
13 Jan 2021 //
EUROPEANPHARMACEUTICALREVIEW
EU approval for ViiV’s Tivicay for children living with HIV
13 Jan 2021 //
PHARMATIMES
ViiV receives EU Marketing Authorisation for the first-ever dolutegravir
13 Jan 2021 //
PRESS RELEASE
ViiV gets EU approval for children`s HIV treatment
13 Jan 2021 //
PHARMAFILE
ViiV gets EU approval for children`s HIV treatment
12 Jan 2021 //
PHARMAFILE
Viatris Announces FDA Tentative Approval of a Pediatric Dolutegravir (DTG)
23 Nov 2020 //
PRNEWSWIRE
Study suggests dolutegravir is the optimal first-line HIV medication
18 Oct 2020 //
EUROPEANPHARMACEUTICALS
Dolutegravir plus lamivudine shows non-inferior HIV-1 in Ph III trials
08 Oct 2020 //
EUROPEALPHARMACEUTICAL
Hetero Labs Unit`s Generic Dolutegravir Receives Tentative Approval In US
29 Sep 2020 //
FDA
ViiV reports promising data from Phase IIIb HIV study of Dovato
21 Aug 2020 //
CLINICALTRIALSARENA
Sun’s dolutegravir 50mg tablet prequalified
18 Aug 2020 //
WHO
ViiV Healthcare announces FDA approval of an expanded indication for Dovato
06 Aug 2020 //
BUSINESSWIRE
US approves first dispersible tablet formulation of Tivicay
15 Jun 2020 //
PHARMATIMES
FDA approves ViiV Healthcare’s Tivicay to treat HIV in children
15 Jun 2020 //
PHARMACEUTICAL
U.S. FDA approves GSK unit`s drug to treat infants and children with HIV
15 Jun 2020 //
REUTERS
GSK ViiV`s Dovato triumphs in #FierceMadness DTC ad contest
05 Apr 2020 //
FIERCEPHARMA
Dolutegravir and the possible risk of neural tube defects
23 Jan 2020 //
MED SAFE
GSK`s plan to take over the HIV drug market hasn`t worked out
07 Jan 2020 //
BIOPHARMADIVE
Roche`s Ocrevus, GSK`s Dovato ads top November TV spending chart
19 Dec 2019 //
FIERCE PHARMA
GSK`s ViiV launches first campaign for new HIV med Dovato
10 Oct 2019 //
FIERCE PHARMA
20-year GSK veteran takes up CSO role at HemoShear
27 Sep 2019 //
FIERCE BIOTECH
Top GSK/ViiV scientist who co-invented an HIV blockbuster books to biotech
25 Sep 2019 //
ENDPTS
Aspen`s drug to prevent preterm birth approved by FDA
13 Sep 2019 //
ECONOMICTIMES
Micro Labs Generic Dolutegravir Sodium Receives Tentative Approval in US
13 Sep 2019 //
FDA
ViiV builds confidence in 2-drug HIV pill with new Dovato data
25 Jul 2019 //
FIERCE PHARMA
ViiV’s Investigational HIV Drug Finds Success in Hard-to-Treat Patient
23 Jul 2019 //
BIOSPACE
Fosun Pharma picks up GSK plant along with rights to make Epivir generic
10 Jul 2019 //
FIERCE PHARMA
GSK`s Dovato meets primary goal in late-stage HIV study
09 Jul 2019 //
REUTERS
